Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. Issue 7 (July 2014)

• Record Type: Journal Article
• Authors: Koszarska, Magdalena; Meggyesi, Nora; Bors, Andras; Batai, Arpad; Csacsovszki, Otto; Lehoczky, Eniko; Adam, Emma; Kozma, Andras; Lovas, Nora; Sipos, Andrea; Krahling, Tunde; Dolgos, Janos; Remenyi, Peter; Fekete, Sandor; Masszi, Tamas; Tordai, Attila; Andrikovics, Hajnalka
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 7(2014:Jul.)
• Page Start: 1510
• Page End: 1517
• Publication Date: 2014-07
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.850163
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Internal tandem duplications (ITDs) of the fms-like tyrosine kinase 3 (<italic>FLT3</italic>) gene occur in about 25% of patients with adult acute myeloid leukemia (AML). The aim of our study was to investigate the frequency of <italic>FLT3</italic>-ITD mutations followed by a detailed analysis of the mutational load and size of ITD insertions in a cohort consisting of 324 patients younger than 60 years old and treated with curative intention. <italic>FLT3</italic>-ITD alone did not influence overall survival (OS) or disease-free survival (DFS). We observed worse OS and DFS for patients with high mutational load indicative for loss of the <italic>FLT3</italic> wild type allele (<italic>p</italic> = 0.010, <italic>p</italic> = 0.038, respectively). In multivariate analyses, patients with <italic>FLT3</italic>-ITD^48–60bp showed worse OS and DFS compared to other groups (<italic>FLT3</italic>-ITD^neg, <italic>FLT3</italic>-ITD^{&lt; 48b}, <italic>FLT3</italic>-ITD^{&gt; 60bp}; <italic>p</italic> = 0.014, <italic>p</italic> = 0.019, respectively). Our novel observation suggested that not only high <italic>FLT3</italic>-ITD load, but also medium-sized ITD insertions (48–60 bp) represented an adverse prognostic subgroup of patients with AML.</p> </abstract>